Тамар Перец

Научные публикации

• Homologous recombination in lung cancer, germline and somatic mutations, clinical and phenotype characterization.
• Heparanase accelerates obesity-associated breast cancer progression.
• The yield of full BRCA1/2 genotyping in Israeli Arab high-risk breast/ovarian cancer patients.
• Variable Features of Juvenile Polyposis Syndrome With Gastric Involvement Among Patients With a Large Genomic Deletion of BMPR1A.
• Life and death of circulating cell-free DNA.
• Lacosamide at therapeutic concentrations induces histone hyperacetylation in vitro.
• Combined Expression of Genetic Adjuvants Via mRNA Electroporation Exerts Multiple Immunostimulatory Effects on Antitumor T Cells.
• Potent Activation of Human T Cells by mRNA Encoding Constitutively Active CD40.
• Regulation of Cellular Heterogeneity and Rates of Symmetric and Asymmetric Divisions in Triple-Negative Breast Cancer.
• Clinical Proteomics of Breast Cancer Reveals a Novel Layer of Breast Cancer Classification.
• Intratumoral immune-biomarkers and mismatch repair status in leiyomyosarcoma -potential predictive markers for adjuvant treatment: a pilot study.
• The yield of full BRCA1/2 genotyping in Israeli high-risk breast/ovarian cancer patients who do not carry the predominant mutations.
• Defects in homologous recombination repair genes are associated with good prognosis and clinical sensitivity to DNA-damaging agents in pancreatic cancer: A case report.
• SYK expression level distinguishes control from BRCA1-mutated lymphocytes.
• Ev vivo organ culture as potential prioritization tool for breast cancer targeted therapy.
• Breast cancer among older women: The influence of age and cancer stage on survival.
• Biomarker-Driven Therapy in Metastatic Gastric and Esophageal Cancer: Real-Life Clinical Experience.
• Phenotypic characteristics of colorectal cancer in BRCA1/2 mutation carriers.
• BRCA mutations and reproduction.
• Soluble SLAMF6 Receptor Induces Strong CD8+ T-cell Effector Function and Improves Anti-Melanoma Activity In Vivo.
• p-STAT3 in luminal breast cancer: Integrated RNA-protein pooled analysis and results from the BIG 2-98 phase III trial.
• Clinical outcomes in ER+ HER2 -node-positive breast cancer patients who were treated according to the Recurrence Score results: evidence from a large prospectively designed registry.
• Treatment inferred from mutations identified using massive parallel sequencing leads to clinical benefit in some heavily pretreated cancer patients.
• Clinical course and outcome of patients with high-level microsatellite instability cancers in a real-life setting: a retrospective analysis.
• Features of Patients With Hereditary Mixed Polyposis Syndrome Caused by Duplication of GREM1 and Implications for Screening and Surveillance.
• Exclusive destruction of mitotic spindles in human cancer cells.
• Adoptive cell therapy: past, present and future.
• Oncotype Dx recurrence score among BRCA1/2 germline mutation carriers with hormone receptors positive breast cancer.
• Heparanase augments insulin receptor signaling in breast carcinoma.
• Spontaneous Activation of Antigen-presenting Cells by Genes Encoding Truncated Homo-Oligomerizing Derivatives of CD40.
• Erratum to: Protease-activated-receptor-2 affects protease-activated-receptor-1-driven breast cancer.
• Recurrent TP53 missense mutation in cancer patients of Arab descent.
• Double-Edged Sword: Women with Breast Cancer Caring for a Spouse with Cancer.
• Immune Monitoring of Patients Treated With a Whole-Cell Melanoma Vaccine Engineered to Express 4-1BBL.
• Pazolimus: pazopanib plus sirolimus following progression on pazopanib, a retrospective case series analysis.
• The Diagnostic and Prognostic Value of sIL-2R as an Immune Biomarker in Head and Neck Cancers.
• Feasibility of Unbiased RNA Profiling of Colorectal Tumors: A Proof of Principle.
• Adjuvant Autologous Melanoma Vaccine for Macroscopic Stage III Disease: Survival, Biomarkers, and Improved Response to CTLA-4 Blockade.
• Serum Thymidine Kinase 1 Activity Following Nephrectomy for Renal Cell Carcinoma and Radiofrequency Ablation of Metastases to Lung and Liver.
• Membrane-attached Cytokines Expressed by mRNA Electroporation Act as Potent T-Cell Adjuvants.
• New ARCHITECT plasma pro-gastrin-releasing peptide assay for diagnosing and monitoring small-cell lung cancer.
• Sorafenib treatment during partial hepatectomy reduces tumorgenesis in an inflammation-associated liver cancer model.
• Assessing Response to New Treatments and Prognosis in Melanoma Patients, by the Biomarker S-100β.
• PH motifs in PAR1&2 endow breast cancer growth.
• Constitutional Mismatch Repair Deficiency in Israel: High Proportion of Founder Mutations in MMR Genes and Consanguinity.
• Unemployment risk and income change after testicular cancer diagnosis: A population-based study.
• The Diagnostic and Prognostic Value of Tumor Markers (CEA, SCC, CYFRA 21-1, TPS) in Head and Neck Cancer Patients.
• Messenger RNA encoding constitutively active Toll-like receptor 4 enhances effector functions of human T cells.
• Gemcitabine in combination with paclitaxel for advanced soft-tissue sarcomas.
• Is (18)F-FDG PET/CT an accurate tool for identifying metastases of lobular breast cancer?
• Characterization of tumor infiltrating natural killer cell subset.
• A phase IIb trial assessing the addition of disulfiram to chemotherapy for the treatment of metastatic non-small cell lung cancer.
• Human T cell crosstalk is induced by tumor membrane transfer.
• Expectations and Level of Satisfaction of Patients and Their Physicians: Concordance and Discrepancies.
• Serum thymidine kinase 1 activity in the prognosis and monitoring of chemotherapy in lung cancer patients: a brief report.
• Genetic features of Lynch syndrome in the Israeli population.
• Macrophage polarization in pancreatic carcinoma: role of heparanase enzyme.
• Silent Partners to Cancer Patients: Formal Caregivers and Oncologists.
• A phase 1/2 of a combination of cetuximab and taxane for "triple negative" breast cancer patients.
• An observational cohort study of bevacizumab and chemotherapy in metastatic colorectal cancer patients: safety and efficacy with analysis by age group.
• Protease-activated-receptor-2 affects protease-activated-receptor-1-driven breast cancer.
• Cost-effectiveness of baseline low-dose computed tomography screening for lung cancer: the Israeli experience.
• Lynch Syndrome in high risk Ashkenazi Jews in Israel.
• Increased proliferative background in healthy women with BRCA1/2 haploinsufficiency is associated with high risk for breast cancer.
• Genetic predisposition to radiation induced sarcoma: possible role for BRCA and p53 mutations.
• Imprinting of lymphocytes with melanoma antigens acquired by trogocytosis facilitates identification of tumor-reactive T cells.
• TL-118-anti-angiogenic treatment in pancreatic cancer: a case report.
• Tumor STAT3 tyrosine phosphorylation status, as a predictor of benefit from adjuvant chemotherapy for breast cancer.
• Safety and efficacy of 188-rhenium-labeled antibody to melanin in patients with metastatic melanoma.
• Determination of molecular markers for BRCA1 and BRCA2 heterozygosity using gene expression profiling.
• [Ctla-4 blockade: a new hope for the immunotherapy of malignant melanoma].
• The prognostic significance of LIAISON(R) CA15-3 assay in primary breast cancer.
• Hypertension as a predictive biomarker in bevacizumab treatment for colorectal cancer patients.
• Comparison of diagnostic and prognostic performance of two assays measuring thymidine kinase 1 activity in serum of breast cancer patients.
• Women's post-chemotherapy parity is affected by offspring number and marital status.
• Control of breast cancer growth and initiation by the stem cell-associated transcription factor TCF3.
• EZH2 promotes a bi-lineage identity in basal-like breast cancer cells.
• Inhibition of matrix metalloproteinase-2 by halofuginone is mediated by the Egr1 transcription factor.
• Association between patient age, volume of breast tissue excised, and local recurrence.
• Long-term outcome of continuous 5-fluorouracil/cisplatin-based chemotherapy followed by chemoradiation in patients with resected gastric cancer.
• [Update: adjuvant trastuzumab in HER2 positive breast cancer].
• The clinical effect of the inhibitor of apopotosis protein livin in melanoma.
• Tissue microarray-based study of patients with lymph node-positive breast cancer shows tyrosine phosphorylation of signal transducer and activator of transcription 3 (tyrosine705-STAT3) is a marker of good prognosis.
• Regulation of human protease-activated receptor 1 (hPar1) gene expression in breast cancer by estrogen.
• Trogocytosis is a gateway to characterize functional diversity in melanoma-specific CD8+ T cell clones.
• HLA-B35 correlates with a favorable outcome following adjuvant administration of an HLA-matched allogeneic melanoma vaccine.
• Complete remission, in BRCA2 mutation carrier with metastatic pancreatic adenocarcinoma, treated with cisplatin based therapy.
• Heparanase powers a chronic inflammatory circuit that promotes colitis-associated tumorigenesis in mice.
• Liver failure on the background of pseudocirrhosis in patients with liver metastasis from breast cancer, who responded to treatment.
• Role of heparanase in radiation-enhanced invasiveness of pancreatic carcinoma.
• Serum thymidine kinase 1 activity in breast cancer.
• Two BRCA1/2 founder mutations in Jews of Sephardic origin.
• Transcutaneous immunization with hydrophilic recombinant gp100 protein induces antigen-specific cellular immune response.
• Circulating tumor M2 pyruvate kinase and thymidine kinase 1 are potential predictors for disease recurrence in renal cell carcinoma after nephrectomy.
• Mitomycin C and vinblastine: an active regimen in previously treated breast cancer patients.
• Cytokines levels, severity of acute mucositis and the need of PEG tube installation during chemo-radiation for head and neck cancer--a prospective pilot study.
• The diagnostic and prognostic value of ProGRP in lung cancer.
• An Ashkenazi founder mutation in the MSH6 gene leading to HNPCC.
• The follow-up of patients with non-muscle-invasive bladder cancer by urine cytology, abdominal ultrasound and urine CYFRA 21-1: a pilot study.
• Autologous melanoma vaccine induces antitumor and self-reactive immune responses that affect patient survival and depend on MHC class II expression on vaccine cells.